Research Article
Functional Polymorphisms and Gene Expression of TLR9 Gene as Protective Factors for Nasopharyngeal Carcinoma Severity and Progression
Table 2
Promoter TLR9 polymorphisms and their associations with the clinicopathological parameters at diagnosis.
| | Clinicopathological parameters | TLR9-1486 | TLR9-1237 | | TT | TC+CC | TT | TC+CC |
| | Age at diagnosis () | | ≤35 | 35 (0.34) | 69 (0.66) | 74 (0.71) | 30 (0.29) | | >35 | 71 (0.33) | 144 (0.67) | 164 (0.76) | 51 (0.24) | | | | 0.910 | | 0.324 | | OR (CI 95%) | 1 | 1.028 (0.62-1.68) | 1 | 0.767 (0.45-1.30) | | Sex () | | Women | 35 (0.35) | 64 (0.65) | 68 (0.69) | 31 (0.31) | | Men | 71 (0.32) | 149 (0.68) | 169 (0.77) | 51 (0.23) | | | | 0.588 | | 0.124 | | OR (CI 95%) | 1 | 1.147 (0.70-1.89) | 1 | 0.662 (0.39-1.12) | | Tumor size () | | T1–T2 | 40 (0.28) | 101 (0.72) | 114 (0.81) | 27 (0.19) | | T3–T4 | 65 (0.36) | 113 (0.64) | 123 (0.69) | 55 (0.31) | | | | 0.124 | | 0.017 | | OR (CI 95%) | 1 | 0.688 (0.43-1.11) | 1 | 1.888 (1.11-3.19) | | Lymph node status () | | N0 | 19 (0.28) | 50 (0.72) | 54 (0.78) | 15 (0.22) | | N+ | 86 (0.34) | 164 (0.66) | 183 (0.73) | 67 (0.27) | | | | 0.283 | | 0.394 | | OR (CI 95%) | 1 | 0.725 (0.40-1.30) | 1 | 1.318 (0.69-2.49) | | Metastasis () | | M0 | 90 (0.32) | 195 (0.68) | 214 (0.75) | 71 (0.25) | | M+ | 8 (0.38) | 13 (0.62) | 17 (0.81) | 4 (0.19) | | | | 0.536 | | 0.792a | | OR (CI 95%) | 1 | 0.750 (0.30-1.87) | 1 | 0.709 (0.23-2.17) | | Clinical stage () | | SI-SII | 7 (0.29) | 17 (0.71) | 21 (0.88) | 3 (0.12) | | SIII-SIV | 98 (0.33) | 196 (0.67) | 215 (0.73) | 79 (0.27) | | | | 0.676 | | 0.149a | | OR (CI 95%) | | 0.824 (0.33-2.05) | 1 | 2.572 (0.75-8.86) |
|
|
aFisher’s exact test; OR: odds ratio; CI: confidence interval.
|
